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Summary
Purpose: The aim of this phase II study was to evaluate the
tumour response of neuroendocrine tumours to targeted
irradiation with the radiolabelled somatostatin analogue
90Y-DOTATOC. In addition, the palliative effect of 90Y-DO-
TATOC treatment on the malignant carcinoid syndrome and
tumour-associated pain was investigated.
Patients and methods: Forty-one patients (mean age 53 years)
with neuroendocrine gastroenteropancreatic and bronchial
tumours were included. Eighty-two percent of the patients had
therapy resistant and progressive disease. The treatment con-
sisted of four intravenous injections of a total of 6000 MBq/m2
90Y-DOTATOC, administered at intervals of six weeks.
Results: The overall response rate was 24%. For endocrine
pancreatic tumours it was 36%. Complete remissions (CR)
were found in 2% (1 of 41), partial remissions (PR) in 22%
(9 of 41), minor response in 12% (5 of 41), stable disease (SD)
in 49% (20 of 41) and progressive disease (PD) in 15% (6 of 41).
The median follow up was 15 months (range 1 month to 36
months). The median duration of response has not been
reached at 26 months. The two-year survival time was 76 ±
16%. Eighty-three percent of the patients suffering from the
malignant carcinoid syndrome achieved a significant reduction
of symptoms. The treatment was well tolerated. A reduction of
pain score was observed in all patients (5 of 41) with morphine
dependent tumour-associated pain. Side effects included grade
III (NCIGC) pancytopenia in 5%, and vomiting shortly after
injection in 23%. No grade III—IV renal toxicity was observed.
Conclusion: Targeted radiotherapy with 90Y-DOTATOC is
a novel, well-tolerated treatment for neuroendocrine tumours
with a remarkable objective response rate, survival time, and
symptomatic response.
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Introduction
Neuroendocrine tumours (NET), previously known as
APUDomas (amine precursor uptake and decarboxyla-
tion adenomas) or sporadic islet-cell tumours, are today
considered to be malignancies derived from the diffuse
neuroendocrine system and share cytochemical features
with melanomas, phaeochromocytomas, medullary thy-
roid carcinoma, and endocrine pancreatic tumours
(EPT) [1]. Malignant neuroendocrine tumours and syn-
dromes have a poor prognosis [1]. Surgery is effective in
less than 5% of all patients [2, 3]. Management of these
tumours includes decreasing the hormone overproduc-
tion. This is considered very important because mortality
in neuroendocrine tumours is often due to the effects of
peptide hypersecretion, rather than tumour progression
[1, 4]. More than 90% of islet-cell tumours express
somatostatin receptors [1]. Endogenous somatostatin
(SRIF: somatotropin release inhibiting factor) acts as
an inhibitor of numerous endocrine and gastrointestinal
functions, notably reducing plasma concentrations of
many peptides including insulin, glucagon, gastrin, se-
cretin, cholecystokinin, and motilin, released by islet-
cell tumours. In addition it inhibits the action of these
hormones. The development of the metabolically stable
somatostatin analogue octreotide, which contains the
biologically active part of somatostatin, resulted in a
new approach to the treatment of neuroendocrine tu-
mours and the carcinoid syndrome [1, 4-7]. In recent
years the aim of many research groups in Nuclear
Medicine and Radiopharmacy has been to develop a
somatostatin analogue which has a high affinity to the
somatostatin receptor and could be linked to a thera-
peutic P-emitting radioisotope. p-Particles emitted from
a radiolabelled peptide bound to a tumour cell also kill
neighboring cells, because the path length of P-particles
can extend over several cell diameters. The crossfire of
P-particles can in theory destroy both somatostatin
receptor- positive and -negative tumour cells. In 1996
Maecke et al. constructed the first promising DOTA
(tetraazacyclo-dodecanetetra-acetic acid) chelated so-
matostatin analogue [8], a hydrophilic peptide vector,
which can be labelled stably with either the p-emitting
therapeutic radionuclide 90Y or diagnostic "'in [9-15].
The affinity of DOTATOC ([90Y-DOTA]-D-Phe'-Tyr3-
octreotide) for somatostatin receptor subtypes SSTR 2
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and SSTR 5, tested in vitro, was found to be very high
[9-15]. In the phase I study we could demonstrate a high
response rate in patients with neuroendocrine tumours
of gastroenteropancreatic or bronchial origin. In this
study the maximum tolerated dose was 6000 MBq/m2.
Thirty-three percent of the patients in a phase I study
who received cumulative doses of > 8500 MBq/m2 90Y-
DOTATOC showed dose limiting renal toxicity (DLT)
[12]. The present study is a prospective phase II trial
investigating the tumour response of neuroendocrine
tumours and the palliative effect of 90Y-DOTATOC
treatment on the malignant carcinoid syndrome.
Patients and methods
Selection of patients
Inclusion criteria included: 1) histologically confirmed diagnosis of
neuroendocrine tumours; 2) tumours had to have an higher uptake in
'"in-DOTATOC- or Octreoscan®-scintiscans than the physiological
liver or renal uptake: 3) no concurrent antitumour treatment; 4) life
expectancy longer than six months; 5) adequate organ function (WHO
grade ^ 2); 6) written informed consent.
Exclusion criteria' Patients younger than 18 years, pregnancy, his-
tory of life-threatening atopic reactions or severe concomitant illness
including severe psychiatric disorders.
The study was approved by the local ethical committee and the
Swiss authorities.
Evaluation of response and toxicity
Four weeks before the first and 2-3 months after the last internal
radiotherapy, tumour response was monitored by either conventional
computed tomography (CT), ultra-sonography (US), magnetic reso-
nance imaging (MRI) or l8F-fluoro-deoxyglucose positron emission
tomography (FDG-PET). FDG-PET served only to determine pro-
gressive disease.
Tumour response was defined according to the WHO standard
criteria. A complete reevaluation of tumour response and time to
progression, including radiographic scans, blood counts and chemis-
tries, was performed by the responsible general practitioners or the
cancer centers caring for the patients every three months after therapy.
Complete blood cell and platelet counts were obtained weekly for at
least six weeks after therapy and every three months thereafter. In
addition thyroid-stimulating hormone (TSH) was measured every
treatment cycle and every three months thereafter. Side effects of 90Y-
DOTATOC treatment were investigated and scored according to the
National Cancer Institute Grading Criteria (NC1-CTC).
Survival
The overall survival of 24 months for all patients was calculated by the
Kaplan-Meier method.
Malignant carcinoid syndrome and tumour associated pain
General practitioners or Cancer Centers were requested to complete
detailed reports concerning the patients symptoms and their analgetic
treatment.
Radiotracer
Maecke et al. developed a DOTA modified somatostatin analogue
named DOTATOC (DOTATOC: 1.4.7,10-tetra-azacyclododecan-
4,7,IO-tricarboxy-methyl-l-yl-acetyl-D-Phe'-Tyr3-Octreo-tide) in a five
step synthetic procedure performed according to GMP practice [8-12].
"'in-DOTATOC was prepared according to previously described pro-
cedures using 8 ug of DOTATOC dissolved in 190 ul 0.4 M sodium
acetate buffer (pH 5.5) with 7 mg gentisic acid and 6 mCi '"inClj (0.05
M HCL, Malhnckrodt Med., Petten, The Netherlands). The solution
was heated at 95 °C for 25 min and quality controlled by using Sep-
Pak®C18 cartridge and high performance liquid chromatography
(HPLC). As a therapeutic radiometal the pure p-emitter 90Yttnum
was linked stably to DOTATOC with preservation of receptor binding
affinity (KD = 2.6 ± 0.5 nM and a labelling yield of > 99.5%).
Treatment
A fractionated treatment protocol was performed with four escalating
intravenous injections (925 MBq/m2, 1295 MBq/m2, 1665 MBq/m2,
2035 MBq/m2) administered at six week intervals resulting in a total of
6000 MBq/m2 90Y-DOTATOC. For each session, patients were hospi-
talized for 2-3 days in accordance with the requirements for legal
radioactivity protection and scintigraphic localization control Thirty
minutes before the injection of each treatment dose. 500 ml of Hart-
mann-Hepa 8%-aminoacid solution (Ringer Lactate Hartmann,
Proteinsteril® Hepa 8%, Mg 5-Sulfat®) were administered to inhibit
the tubular reabsorption of the radiopeptide DOTATOC. In each 90Y-
DOTATOC session, 3 mCi of '"in-DOTATOC were injected simulta-
neously in order to check DOTATOC binding and tumour response.
One, twenty-four and forty-eight hours p.i. static images (5 min/image)
were acquired by using a large field of view gamma camera (Siemens
Diacam), equipped with a medium energy parallel hole collimator
(matrix 64 x 64, zoom 1).
Results
Patients
Forty-one patients entered the study. The characteristics
are given in Table 1. The median age of jhe_rjatients.(_male_
n - 25, £emale-«-= 16) was 50.6 years^range_13i=J.rl_years.
Tumour histologies were as follows: endocrine pancre-
atic tumours (three insulinomas and one gastrinoma) in
fourteen patients, intestinal neuroendocrine tumours in
eight patients, bronchial neuroendocrine tumours in
seven patients, neuroendocrine tumours of unknown
origin in eight patients and finally one paraganglioma,
one carotid body tumour, one phaeochromocytoma and
one primitive neuroectodermal tumour. Eighty-three
percent of the patients (34 of 41) showed a progressive
disease before treatment (Table 2). Seventeen percent
(7 of 41) had a stable disease before entering the study;
none of these patients had any antitumour therapy at
least two years before 90Y-DOTATOC-treatment. The
details of pre-treatment are shown in Table 1. Thirty-
nine patients received four cycles of treatment within
twenty-four weeks; in two patients treatment had to be
stopped after the second cycle due to tumour progres-
sion.
Evaluation of tumour response
The tumour response of the individual tumour types are
demonstrated in Table 2.
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Table I. Patients and previous treatments.
Resection Chemo- Chemo- Octreotide Interferon-a External Liver-trans-
embolisation therapy radiotherapy plantation
EPT(/i=14)
Intestinal NET (n = 8)
Bronchial NET (n = 7)
NET of unknown origin (n = 8)
Others (n = 4)
8
7
7
3
2
27
6
4
3
2
15
I
Table 2. Tumour response (WHO standard criteria).
E P T ( n = 14)
Intestinal NET (n = 8)
Bronchial NET (n = 7)
NET of unknown origin (n = 8)
Others (n = 4)
All (n = 41)
Progression
before
treatment
% (n)
71 (10)
88(7)
100 (7)
50(4)
100 (4)
83 (34)
Complete
remissions
(CR)
n
_
i
-
-
i
Partial
remissions
(PR)
n
5
1
1
2
-
9
Stable
disease
(SD)
n
1
6
5
5
2
25
Progressive
disease within
or after
treatment
2
1
-
1
2
6
Overall
tumour
response
%
36
13
29
25
0
24
CR. PR, SD
" (%)
12(86)
7(88)
7(100)
7(89)
2(50)
35 (85)
Tumour response was monitored by conventional
computed tomography (CT) in 24 cases, ultrasonogra-
phy in nine cases and magnetic resonance imaging
(MRI) in seven cases. In one patient the result of FDG-
PET served to determine progressive disease by counting
the rate of hypermetabolic lesions. In addition scinti-
graphic assessments were performed in all 41 patients.
Even though there are no denned response criteria for
scintigraphy, the findings were concordant with the
radiological response in all cases.
Complete remissions were found in 1 of 41 (2%),
partial remissions in 9 of 41 (22%) and stable disease in
25 of 41 (61%). The overall tumour response rate was
24%. For patients with EPT, the response rate was 36%.
CR or PR were found in liver metastases, diameter 1-7
cm, in eight patients; in lymph nodes (paratracheal,
retroperitoneal and mediastinal), diameter 1,5-2 cm, in
three patients; in pancreatic primaries, diameter 5-7 cm
in two patients. CR could be determined in liver metas-
tases with a diameter < 4 cm in two patients and in
lymph nodes with a diameter < 2 cm in two patients.
The median duration of response has not been reached
at 26 months. Six of nine patients (67%) have shown
continuous remission to date. All responding patients had
progressive disease prior to 90Y-DOTATOC-treatment.
In four patients 90Y-DOTATOC was able to eliminate
all liver metastases, as determined by CT-scan. One
patient who had been bedridden because of neuroendo-
crine spinal metastases achieved a marked improvement
in neurological function.
Survival
After a median follow-up of 15 months (range 2 to 26
months) 8 of 41 (20%) patients had died after therapy.
Tumour-related reasons for death were: tumour progres-
sion in five patients, and a gastrointestinal bleeding in
one patient caused by tumour infiltration, as determined
by autopsy. Also confirmed by autopsy findings, tumour-
unrelated reasons for death were a lethal complication
after cardiac surgery six months after treatment in
one patient, and acute pneumonia in one patient. No
death could be related to the 90 Y-DOTATOC-treatment.
Figure 1 shows the two-year survival of our study group.
The overall survival at 24 months including the 95%
confidence interval was calculated to be 76% (60%-92%).
Toxicity
Eleven patients (27%) developed nausea, vomiting and
flush during the 90Y-DOTATOC injection. Three pa-
tients showed nausea grade 1 after each cycle and three
patients exhibited nausea grade 1 for two weeks.
Twenty-two percent (n = 9) of the patients showed
lymphocytopenia grade 1, 7% (n = 3) grade 2 and 5%
(/? = 2) grade 3. After 3-4 weeks values returned to
baseline, and the treatment could be given according to
protocol to all patients.
After the third cycle of 90 Y-DOTATOC-treatment,
two patients developed both anamia grade 3 and throm-
bocytopenia grade 3. Both patients started the treatment
with anaemia and thrombocytopenia grade 2. Complete
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Figure I. A plot of overall actuarial survival of all 41 patients calcu-
lated by the Kaplan-Meier method
TSH-measurement data of 4 values in 21 patients and
incomplete data of 2-3 measurements in 20 patients
showed normal values throughout the whole trial.
During the trial and the follow up no renal toxicity
was observed.
Malignant carcinoid syndrome
Six of forty-one patients suffered from the Malignant
Carcinoid syndrome in spite of taking octreotide before
90Y-DOTATOC-therapy. Six of them suffered from diar-
rhea grade 2, 6 from flushes, 5 from vomiting and 2 from
pellagra. After treatment, symptoms were significantly
improved in four of six patients (by more than 1 grade on
the NCI-CTC score) or completely disappeared in two
of six patients.
Tumour-associated pain and weakness
Twenty-two of forty-one patients suffered from pain
mainly caused by bone or liver metastases. Five of them
had morphine-dependent pain. After 90Y-DOTATOC-
treatment all of these patients were able to change to
non-steroidal anti-inflammatory drugs (NSAID, three
of five) or to discontinue analgetic drugs altogether (two
of five). All of these patients had taken increasing doses
of NSAID before starting morphine medication. The
improvement of pain was not correlated to tumour
response.
Discussion
For metastasized NET, biotherapy with the somatosta-
tin analogues octreotide or lanreotide is the treatment of
choice [4, 16]. Somatostatin therapy with long-acting
somatostatin analogues is reported to cause a tumour
response in 12% of patients with EPT and a stabilization
of disease in 25%-30% of patients [17]. Oeberg found
biochemical responses to a long-acting formulation in
40% to 70%, but objective tumour response (WHO) only
in 4%-10% [4]. In one further study, in which carcinoids
were treated with lanreotide, Rusznniewski et al. showed
subjective response rates of 50%, biochemical response
rates of 42% but no objective tumour response [17].
Alternatively, interferon-alpha is reported to have a
biochemical response rate of 43% in patients with EPT
and an objective response rate of 11% [4, 17, 18]. In the
case of tumour progression or escalating malignant
carcinoid syndrome under the above-mentioned thera-
pies, dose escalation of somatostatin analogues can be
tried or alternatively a combination of interferon-alpha
with a somatostatin analogue [1, 4, 17, 18]. If these treat-
ments fail patients are usually treated with chemother-
apy (streptozotocin and 5-fluorouracil or cisplatinum
and etoposide) [4, 16]. Randomized trials have not
established a standard chemotherapy and most regimens
have response rates of less than 20% [4]. Furthermore
patients treated with polychemotherapy usually have to
deal with considerable side effects [16, 18-20].
Treatment with 90Y-DOTATOC resulted in an objec-
tive response of 24% and even 36% for patients with
EPT. Most of the patients were pretreated and had
progressive disease. Tumour stabilization could be
achieved in 85% of the patients. The two-year overall
survival of 76 ± 16% compares favorably to the reports
in the literature for patients with advanced and treat-
ment-resistant tumours [21-23]. 90Y-DOTATOC treat-
ment was well tolerated and toxicity was generally mild.
Lastly we could show a significant effect of 90Y-DOTA-
TOC in palliation both concerning the malignant carci-
noid syndrome and tumour-associated pain. This benefit
seemed to be independent of an objective response. The
level of pain was not scored in a prospective standard
manner and may therefore be biased. However our more
recent unpublished results from ongoing studies confirm
this observation. The benefit could be in part related to
the reduction of hormone oversecretion and a postra-
diation neurotrauma.
The previously reported renal toxicity was not found
in this trial [12]. Although serum creatinine levels repre-
sent a relatively insensitive marker of global renal func-
tion, and although a median follow up of 15 months is a
short time, cumulative doses <7400 MBq/m2 seem to
be tolerated well by the kidneys [12]. Even though the
pituitary gland expresses low levels of somatostatin
receptors, it was of importance to evaluate the possible
toxic effects of 90Y-DOTATOC on the function of this
organ. We could not detect any adverse effect on the
pituitary gland by 90 Y-DOTATOC.
Our study suggests that 90Y-DOTATOC is probably a
very effective therapeutic alternative to the chemo- and
biotherapies known to date. Experimental studies have
shown the correlation between the amount of radio-
activity applied and the tumour response obtained. To-
day the radioactive dose of 90 Y-DOTATOC-treatment is
limited by its renal toxicity, because elevated doses raise
the risk of renal damage. But if renal peptide reabsorp-
tion could be reduced significantly, 90Y-DOTATOC-
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treatment could possibly become a first line therapy
for metastasized neuroendocrine tumours. One way to
improve the present results could be the combination
of 90Y-DOTATOC with other forms of therapies for
neuroendocrine tumours.
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